8,969 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Valence8 US LP

Valence8 US LP purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,969 shares of the specialty pharmaceutical company's stock, valued at approximately $999,000. Jazz Pharmaceuticals accounts for 0.4% of Valence8 US LP's investment portfolio, making the stock its 13th biggest position.

A number of other hedge funds also recently bought and sold shares of JAZZ. Vanguard Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company's stock worth $776,551,000 after purchasing an additional 84,941 shares in the last quarter. LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 4.2% in the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock valued at $264,750,000 after acquiring an additional 99,705 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Capital World Investors acquired a new position in Jazz Pharmaceuticals in the first quarter valued at approximately $171,943,000. Finally, Baupost Group LLC MA increased its stake in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock valued at $136,000,000 after purchasing an additional 440,552 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on JAZZ shares. TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Wells Fargo & Company dropped their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday. Finally, StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $175.33.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 1.2 %

Shares of JAZZ stock traded up $1.52 on Friday, reaching $126.62. 665,928 shares of the stock were exchanged, compared to its average volume of 678,412. The stock has a market cap of $7.66 billion, a P/E ratio of 17.62, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a 50 day moving average of $113.29 and a two-hundred day moving average of $110.62. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.